Similarly, in an advanced prostate cancer model, Gnetin C (7 mg/kg/bw, i.p.)significantly blocked tumor progression through MTA1/Akt/mTOR signaling [53], suggesting that Gnetin C could be effective not only in cancer chemoprevention and interception but also as an active therapeutic strategy (Table 2). Here, MTA1 is linked to prostate carcinoma.